Evidence map›Paper›PMID 30145664›Full record

Trial reportDiabetologia2018

Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial.

Kimberly J Nahon, Fleur Doornink, Maaike E Straat, Kani Botani, Borja Martinez-Tellez, Gustavo Abreu-Vieira, Jan B van Klinken, Gardi J Voortman, Edith C H Friesema, Jonatan R Ruiz and 8 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02294084 (The Effect of Sitagliptin on Brown Adipose Tissue and Whole-body Metabolism in Overweight Pre-diabetic Men), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02294084 phase4completednot on this map

The Effect of Sitagliptin on Brown Adipose Tissue and Whole-body Metabolism in Overweight Pre-diabetic Men

TypeinterventionalSponsorIngrid JazetRan2014 to 2016Enrolled30ConditionsNeoplasms, Adipose TissueArmsSitagliptin, placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Body composition changes in diabetes and aging.Journal of diabetes and its complications · 2019
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Kimberly J NahonDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Fleur DoorninkDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Maaike E StraatDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Kani BotaniDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Borja Martinez-TellezDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Gustavo Abreu-VieiraDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Jan B van KlinkenDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Gardi J VoortmanDivision of Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
Edith C H FriesemaDivision of Vascular Medicine, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
Jonatan R RuizPROFITH 'Promoting Fitness and Health through Physical Activity' research group, Department of Physical Education and Sport, Faculty of Sport Sciences, University of Granada, Granada, Spain.
Floris H P van VeldenDivision of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
Lioe-Fee de Geus-OeiDivision of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
Frits SmitDivision of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
Lenka M Pereira Arias-BoudaDivision of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
Jimmy F P BerbéeDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Ingrid M JazetDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Mariëtte R BoonDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands. m.r.boon@lumc.nl.
Patrick C N RensenDivision of Endocrinology, Department of Medicine, Leiden University Medical Center, post zone C7Q, P. O. Box 9600, 2300 RC, Leiden, the Netherlands.
Leiden University Medical Center · NLErasmus MC · NLUniversidad de Granada · ESAlrijne Ziekenhuis · NL

Funding

Dutch Diabetes Research Foundation 2015.81.1808Netherlands Heart Foundation 2009T038
6 · The paper itself

Abstract

aims/hypothesisThe aim of this study was to evaluate the effect of sitagliptin on glucose tolerance, plasma lipids, energy expenditure and metabolism of brown adipose tissue (BAT), white adipose tissue (WAT) and skeletal muscle in overweight individuals with prediabetes (impaired glucose tolerance and/or impaired fasting glucose).

methodsWe performed a randomised, double-blinded, placebo-controlled trial in 30 overweight, Europid men (age 45.9 ± 6.2 years; BMI 28.8 ± 2.3 kg/m

resultsOne participant from the sitagliptin group was excluded from analysis, due to a distribution error, leaving 29 participants for further analysis. Sitagliptin, but not placebo, lowered glucose excursion (-40%; p < 0.003) during OGTT, accompanied by an improved insulinogenic index (+38%; p < 0.003) and oral disposition index (+44%; p < 0.003). In addition, sitagliptin lowered serum concentrations of triacylglycerol (-29%) and very large (-46%), large (-35%) and medium-sized (-24%) VLDL particles (all p < 0.05). Body weight, body composition and energy expenditure did not change. In skeletal muscle, sitagliptin increased mRNA expression of PGC1β (also known as PPARGC1B) (+117%; p < 0.05), a main controller of mitochondrial oxidative energy metabolism. Although the primary endpoint of change in BAT volume and activity was not met, sitagliptin increased [ CONCLUSIONS/

interpretationTwelve weeks of sitagliptin in overweight, Europid men with prediabetes improves glucose tolerance and lipid metabolism, as related to increased [

trial registrationClinicalTrials.gov NCT02294084.

fundingThis study was funded by Merck Sharp & Dohme Corp, Dutch Heart Foundation, Dutch Diabetes Research Foundation, Ministry of Economic Affairs and the University of Granada.

Indexed as

Adipose Tissue, BrownAdipose Tissue, WhiteAdultBlood GlucoseBody WeightCarrier ProteinsDipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodEnergy MetabolismHumansMaleMiddle AgedMuscle, SkeletalOverweightPrediabetic StateRNA-Binding ProteinsBlood GlucoseCarrier ProteinsDipeptidyl-Peptidase IV InhibitorsPPARGC1B protein, humanRNA-Binding ProteinsSitagliptin PhosphateBrown adipose tissueDiabetes riskDPP4 inhibitorDyslipidaemiaEnergy expenditureObesityPrediabetesSkeletal muscle

Identifiers

PMID30145664
PMCPMC6182651
OpenAlexW2888377953

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.